Genelux (GNLX) Net Shares Issued and Repurchased (2022 - 2026)
Genelux (GNLX) posted Net Shares Issued and Repurchased of $288154.0 for Q1 2026, down 84.04% on a QoQ basis from $1.8 million in Q4 2025.
Analysis
Genelux (GNLX) Net Shares Issued and Repurchased (2022 - 2026) Analysis & Trends
Genelux has reported Net Shares Issued and Repurchased for 5 years, with the latest figure at $288154.0 in Q1 2026.
- On a quarterly basis, Net Shares Issued and Repurchased changed N/A year-over-year to $288154.0 in Q1 2026; TTM through Mar 2026 was $288154.0, a N/A change from a year earlier, with the FY2025 full-year figure at $1.8 million, changed N/A from the prior year.
- Net Shares Issued and Repurchased was $288154.0 for Q1 2026 at Genelux, down from $1.8 million in the prior quarter.
- The five-year high for Net Shares Issued and Repurchased was $1.8 million in Q4 2025, with the low at $51581.0 in Q1 2024.
- Average Net Shares Issued and Repurchased over 5 years is $700595.7, with a median of $473896.0 recorded in 2023.
- The largest YoY upside for Net Shares Issued and Repurchased was 364.39% in 2023 against a maximum downside of 364.39% in 2023.
- Over 5 years, Net Shares Issued and Repurchased stood at $247785.0 in 2022, then jumped by 364.39% to $1.2 million in 2023, then slumped by 95.52% to $51581.0 in 2024, then jumped by 3400.76% to $1.8 million in 2025, then sank by 84.04% to $288154.0 in 2026.
- The last three Net Shares Issued and Repurchased figures came in at $288154.0 (Q1 2026), $1.8 million (Q4 2025), and $51581.0 (Q1 2024), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Shares Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | - |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | - |
| 10 | Genelux | 108.17 Mn | 108.17 Mn | - | 288,154.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 288,154.00 |
| Dec 31, 2025 | 1.81 Mn |
| Mar 31, 2024 | 51,581.00 |
| Dec 31, 2023 | 1.15 Mn |
| Sep 30, 2023 | 659,638.00 |
| Dec 31, 2022 | 247,785.00 |